inhibit
hostencod
target
cyclophilin
provid
opportun
gener
potent
high
barrier
resist
antivir
treatment
broad
rang
viral
diseas
howev
mani
hosttarget
agent
natur
product
difficult
optim
use
synthet
chemistri
alon
describ
orthogon
combin
bioengin
semisynthet
chemistri
optim
druglik
properti
sanglifehrin
known
cyclophilin
inhibitor
mix
nonribosom
peptidepolyketid
origin
order
gener
drug
candid
formerli
potent
inhibitor
hbv
hcv
replic
show
minim
inhibit
major
drug
transport
high
barrier
gener
hcv
resist
treatment
chronic
viral
diseas
direct
inhibit
viral
target
frequent
lead
rapid
develop
virallyencod
resist
therapi
target
host
protein
involv
viral
lifecycl
offer
opportun
rais
barrier
gener
resist
gener
antivir
abl
treat
broad
rang
viral
diseas
howev
hinder
past
rel
rariti
target
essenti
viru
nonessenti
host
inher
complex
discov
develop
drug
effect
target
protein
small
molecul
approv
anticanc
drug
natur
origin
either
directli
deriv
oppos
natur
product
approv
use
antivir
therapi
although
inspir
antivir
nucleosid
analogu
mani
bacteri
natur
product
np
includ
welldescrib
polyketid
class
shown
bind
inhibit
mammalian
cellular
protein
includ
viral
hostencod
target
cyclophilin
vatpas
produc
low
cost
good
ferment
frequent
lead
compound
excel
potenc
target
good
cellular
penetr
howev
natur
product
often
display
polypharmacolog
less
optim
mammalian
pharmacokinet
physicochem
properti
tool
avail
optim
np
ever
increas
specif
bioengin
propos
way
reinvigor
natur
product
drug
discoveri
past
semisynthet
approach
frequent
use
rout
improv
druglik
properti
natur
product
hit
howev
avail
semi
synthet
option
predetermin
array
function
group
np
contrast
bioengin
option
predetermin
biosynthet
pathway
potenti
chang
thu
orthogon
avail
semisynthesi
whole
genom
sequenc
straightforward
easili
afford
np
class
modular
polyketid
synthas
pkss
knowledg
dna
sequenc
encod
biosynthet
gene
cluster
enabl
rapid
understand
gene
product
function
combin
improv
techniqu
dna
transfer
rapid
target
alter
biosynthet
gene
provid
power
platform
focus
drug
discoveri
effort
aim
improv
druglik
properti
pharmacokinet
reduc
offtarget
effect
bioengin
techniqu
readili
combin
semisynthesi
identifi
molecul
improv
properti
particular
inactiv
precursor
pathway
allow
mutasynthesi
process
feed
synthet
analogu
precursor
incorpor
biosynthet
final
molecul
enabl
combinatori
element
bioengin
cyclophilin
class
peptidylprolyl
isomeras
protein
catalys
cistran
isomer
peptid
bond
preced
prolyl
residu
knockout
studi
sever
speci
includ
mice
human
cell
confirm
limit
effect
cellular
growth
surviv
howev
cyclophilin
recruit
host
cell
shown
essenti
role
mani
viral
lifecycl
initi
cyclophilin
shown
incorpor
virion
involv
viral
replic
express
level
patient
relat
speed
progress
aid
cyclophilin
isomeras
activ
potenti
cyclophilin
b
cyclophilin
shown
requir
hcv
replic
describ
use
combin
bioengin
semisynthet
approach
optim
druglik
properti
sanglifehrin
np
cyclophilin
inhibitor
gener
formerli
preclin
analysi
reveal
molecul
display
vitro
inhibit
hbv
hcv
potent
vitro
oral
vivo
inhibit
previou
semisynthet
derivat
replac
spirolactam
fragment
sanglifehrin
led
gener
sangamid
molecul
improv
solubl
potenc
select
approach
move
immunosuppress
np
tool
compound
appropri
chemic
genet
compound
could
reason
pursu
therapeut
agent
use
bioengin
make
alter
macrocycl
portion
molecul
chang
could
otherwis
done
without
complex
total
synthesi
major
aim
work
improv
druglik
properti
final
molecul
specif
manipul
part
molecul
involv
cyclophilin
bind
gene
cluster
requir
biosynthesi
sanglifehrin
publish
gener
sanglifehrin
requir
thirteen
typic
pk
extens
modul
three
nrp
nonribosom
peptid
synthetas
modul
incorpor
lvalin
metaltyrosin
lpiperaz
acid
addit
crotonylcoa
reductasecarboxylas
ccr
present
gener
pk
starter
unit
iter
type
pk
requir
suppli
uniqu
malonylcoa
extend
unit
phenylalanin
hydroxylas
produc
nrp
extend
unit
metaltyrosin
lphenylalanin
analysi
publish
crystal
structur
sanglifehrin
analogu
spirolactam
fragment
remov
suggest
manipul
electron
metaltyrosin
moieti
might
lead
improv
bind
cyclophilin
achiev
inactiv
sfaa
gene
encod
phenylalanin
hydroxylas
respons
metaltyrosin
biosynthesi
delet
sfaa
carri
homolog
recombin
follow
conjug
plasmid
contain
appropri
delet
construct
sp
use
standard
techniqu
led
strain
due
lack
metaltyrosin
product
produc
sanglifehrin
unless
fed
metaltyrosin
analogu
screen
carri
feed
select
appropri
metaltyrosin
analogu
order
determin
abil
gener
sanglifehrin
analogu
see
figur
ferment
analogu
success
accept
substrat
scale
allow
isol
new
sanglifehrin
antivir
activ
adm
properti
analogu
analys
best
analogu
subject
semisynthesi
yield
correspond
sangamid
describ
previous
result
sangamid
analys
antivir
activ
adm
properti
chosen
potenti
drug
candid
data
shown
deriv
sanglifehrin
result
incorpor
semisynthesi
replac
spirolactam
contain
portion
sanglifehrin
tertiari
hydroxam
amid
moieti
tabl
sangamid
test
best
combin
properti
tabl
includ
potent
inhibit
cypa
ppias
activ
inhibit
hcv
replicon
one
issu
cyclosporinbas
cyclophilin
inhibitor
offtarget
inhibit
transport
protein
alisporivir
exampl
inhibit
multipl
transport
protein
includ
involv
bilirubin
transport
inhibit
thought
mechan
dose
limit
hyperbilirubinaemia
compound
also
drugdrug
interact
concern
inhibit
xenobiot
transport
pgp
bsep
comparison
inhibit
transport
use
vesicular
transport
uptak
transport
inhibit
assay
vitro
inhibit
xenobiot
transport
pgp
bsep
reveal
whilst
alisporivir
csa
potent
inhibit
mani
figur
previous
state
compound
moss
et
al
show
minim
inhibit
see
tabl
test
effect
bilirubin
level
dose
three
mice
mgkgday
day
case
almost
increas
seen
either
bilirubin
liver
enzym
measur
end
studi
see
supplementari
inform
tabl
confirm
bioavail
follow
oral
dose
singl
oral
dose
mgkg
given
group
mice
rat
dog
case
blood
concentr
maintain
hcv
ec
h
post
dose
figur
liver
level
found
fold
higher
blood
level
fold
higher
plasma
level
reveal
concentr
within
target
organ
treatment
hepat
diseas
see
supplementari
inform
tabl
analysi
organ
rat
includ
brain
heart
lung
reveal
much
lower
exposur
follow
oral
dose
compar
blood
liver
probabl
due
first
pass
extract
liver
recent
standard
care
treatment
chronic
hcv
infect
combin
interferon
ribavirin
month
use
recent
approv
high
barrier
resist
drug
nucleotid
polymeras
inhibitor
npi
sofosbuvir
lead
high
level
viral
clearanc
cyclophilin
inhibit
one
mechan
action
hcv
inhibit
consist
show
high
barrier
resist
phase
trial
patient
clear
viru
treat
week
mgday
alisporivir
monotherapi
alisporivir
nonimmunosuppress
semisynthet
deriv
cyclosporin
potent
cyclophilin
inhibitor
phase
iii
trial
treatment
hcv
infect
could
provid
suitabl
altern
backbon
use
interferonfre
combin
comparison
inhibitori
potenti
semisynthet
sangamid
alisporivir
hcv
replicon
reveal
much
potent
assay
similarli
activ
genotyp
test
see
tabl
analysi
effect
increas
level
either
human
serum
fc
also
confirm
effect
antivir
potenc
addit
serum
see
supplementari
inform
tabl
compar
barrier
resist
hcv
cell
serial
passag
week
presenc
increas
concentr
alisporivir
coloni
amplifi
cellular
rna
extract
analyz
rtqpcr
alisporivirresist
replicon
previous
describ
clinic
relev
mutat
consist
found
clone
analyz
case
resist
replicon
clone
analyz
contain
five
mutat
test
separ
replicon
contain
individu
mutat
list
mutat
shown
confer
resist
alon
combin
five
mutat
led
resist
compar
wildtyp
previou
report
cyclophilin
inhibitor
cyclosporin
inhibitori
effect
hbv
replic
therefor
test
two
vitro
model
look
inhibitori
activ
first
involv
transfect
cell
hbv
dna
presenc
alisporivir
dmso
day
amount
de
novo
hbv
protein
hbsag
hbeag
present
cell
extract
supernat
quantifi
elisa
triplic
data
shown
tabl
reveal
alisporivir
potent
inhibit
hbv
replic
concentr
addit
assay
run
use
cell
stabli
express
replic
hbv
treat
dmso
alisporivir
three
concentr
effect
hbv
replic
monitor
treat
cell
test
articl
relev
concentr
day
remov
supernat
retreat
analyz
addit
h
hbsag
elisa
hbeag
elisa
hbv
dna
triplic
cell
extract
supernat
assay
confirm
dose
depend
effect
hbv
replic
final
time
point
although
cyclophilin
inhibitor
current
clinic
develop
treatment
infect
alisporivir
origin
develop
inhibitor
replic
show
mean
log
drop
viral
load
follow
day
dose
hivhcv
coinfect
patient
therefor
test
comparison
alisporivir
hela
inhibitori
fac
assay
see
improv
inhibit
vitro
hcv
replicon
carri
inhibitori
assay
found
potent
regard
ec
see
tabl
term
maxim
viral
inhibit
seen
reach
inhibit
sanglifehrin
analogu
includ
cyclosporin
alisporivir
data
similar
repeat
jurkat
cell
activ
peripher
blood
tlymphocyt
macrophag
one
concern
develop
alisporivir
treatment
presenc
natur
isol
alisporivir
resist
genotyp
test
lab
gener
natur
isol
found
activ
case
shown
potent
vitro
inhibit
oral
bioavail
effect
viral
replic
scidhu
thyliv
mous
model
assess
model
well
valid
standard
hiv
therapi
thought
highli
reproduc
model
relev
clinic
effect
enabl
comparison
data
previou
studi
approv
agent
model
alisporivir
dose
oral
bidaili
day
start
one
day
inocul
viru
mgkgday
mgkgday
administr
gave
log
reduct
rna
potent
concentr
test
alisporivir
protect
thymocyt
reduc
rna
level
see
figur
overt
sign
toxic
seen
mice
dose
level
potenc
compar
well
data
previous
publish
stoddart
et
al
log
rna
log
drop
seen
follow
dose
pronounc
approv
therapi
efavirenz
atazanavir
emtricitabin
nevirapin
show
log
viral
rna
reduct
day
bidaili
dose
mgkg
cyclophilin
inhibitor
gener
use
combin
semisynthet
bioengin
method
frequent
use
independ
past
less
commonli
use
togeth
enabl
combinatori
approach
natur
product
drug
discoveri
led
select
compound
potent
cyclophilin
inhibit
antivir
potenc
versu
hbv
hcv
reduc
offtarget
transport
inhibit
compar
parent
compound
sanglifehrin
fluorin
introduc
compound
mutasynthesi
method
success
introduc
substitut
pattern
less
invas
way
semisynthet
chemistri
second
gener
cyclophilin
inhibitor
potenti
therapeut
applic
number
area
particular
chronic
viral
infect
due
potenc
high
barrier
resist
activ
multipl
step
viral
lifecycl
oral
bioavail
also
worth
note
recent
public
suggest
compound
might
also
addit
impact
interferon
regulatori
factor
long
implic
escap
certain
virus
hcv
hiv
immun
system
whilst
cyclophilin
inhibitor
exhibit
inhibit
virus
shown
activ
wide
varieti
rna
virus
eg
coronavirus
hiv
hcv
dna
virus
hcmv
hbv
vzv
therefor
tempt
specul
cyclophilin
inhibitor
may
step
direct
agent
broad
antivir
activ
also
anticip
era
rapid
genom
sequenc
gene
synthesi
bioengin
applic
continu
becom
amen
offer
flexibl
rout
improv
natur
product
potent
inhibit
cellular
target
less
optimum
druglik
properti
hope
futur
bioengin
semisynthesi
use
frequent
combin
optim
natur
product
aim
select
candid
clinic
develop
frame
delet
sfaa
gene
code
tyrosin
hydroxylas
carri
use
doubl
recombin
recombin
strain
gener
could
fed
methyl
propano
hydrochlorid
salt
grown
appropri
ferment
condit
gener
detail
avail
supplementari
inform
synthes
three
step
use
protocol
compound
briefli
treat
via
modifi
sharpless
dihydroxyl
condit
form
diol
subsequ
cleav
gener
allyl
aldehyd
action
sodium
period
final
result
allyl
aldehyd
coupl
suitabl
amid
hornerwadsworthemmon
coupl
condit
solubl
analysi
plasma
protein
bind
intraven
oral
pharmacokinet
toxicolog
carri
use
standard
method
shanghai
chempartn
shanghai
efflux
assay
carri
solvo
biotechnolog
hungari
cyprotex
uk
detail
avail
supplementari
inform
test
articl
test
capac
block
interact
cypa
hcv
elisa
specif
produc
purifi
recombin
gst
gstcypa
protein
conduct
elisa
nunc
maxisorb
strip
plate
coat
gst
gstcypa
h
block
recombin
ngml
ad
well
bind
buffer
mm
tri
ph
nacl
glycerol
mm
dtt
h
captur
subsequ
detect
use
mous
antihi
antibodi
clontech
rabbit
antimousehorseradish
peroxidas
phosphatas
hrp
antibodi
dilut
test
effect
test
articl
complex
format
increas
concentr
test
articl
ad
gstcypa
togeth
recombin
experi
conduct
twice
data
triplic
present
ic
inhibit
ppias
activ
cypa
use
compar
inhibitori
potenti
sanglifehrin
deriv
indic
bind
affin
cypa
ppias
activ
recombin
cypa
produc
thrombin
cleavag
gstcypa
determin
follow
rate
hydrolysi
nsuccinylalaalaprophepnitroanilid
chymotrypsin
chymotrypsin
hydrolyz
tran
form
peptid
hydrolysi
ci
form
concentr
maxim
use
stock
dissolv
trifluoroethanol
contain
mm
licl
limit
rate
cistran
isomer
cypa
equilibr
hour
select
sanglifehrin
deriv
use
drug
concentr
rang
nm
reaction
start
addit
peptid
chang
absorb
monitor
spectrophotometr
data
point
per
sec
blank
rate
hydrolysi
absenc
cypa
subtract
rate
presenc
cypa
initi
rate
enzymat
reaction
analyz
firstord
regress
analysi
time
cours
chang
absorb
sanglifehrin
deriv
exhibit
antippias
activ
correl
well
capac
prevent
interact
analyz
elisa
pulldown
antihcv
assay
huh
cell
perform
seed
cell
per
well
tissu
cultur
treat
white
view
plate
packard
canberra
canada
dulbecco
modifi
essenti
media
dmem
supplement
follow
incub
h
co
medium
remov
serial
dilut
complet
dmem
without
test
compound
ad
total
volum
day
incub
cell
cultur
medium
remov
luciferas
activ
determin
use
luciferas
assay
system
promega
leiden
netherland
luciferas
signal
measur
use
tecan
switzerland
rel
luminesc
unit
convert
percentag
untreat
control
effect
concentr
ec
defin
concentr
compound
reduc
luciferas
signal
assess
potenti
cytostat
effect
evalu
inhibitor
cell
seed
densiti
cell
per
well
plate
complet
dmem
serial
dilut
test
compound
complet
dmem
ad
h
seed
cell
allow
prolifer
day
cell
number
determin
mean
phenazinemethosulf
mtspm
method
promega
cc
valu
deriv
doserespons
curv
repres
concentr
metabol
activ
cell
would
reduc
metabol
activ
untreat
cell
select
index
si
indic
therapeut
window
compound
calcul
cc
ec
replicon
cell
subgenom
replicon
genotyp
grown
dmem
fetal
bovin
serum
fb
penicillinstreptomycin
penstrep
glutamin
nonessenti
amino
acid
co
incub
cell
cultur
reagent
purchas
mediatech
herndon
va
replicon
cell
trypsin
seed
cell
per
well
plate
media
without
follow
day
cultur
medium
replac
dmem
contain
compound
serial
dilut
presenc
fb
cell
contain
hcv
replicon
seed
plate
test
articl
serial
dilut
dmem
plu
fb
dilut
compound
appli
appropri
well
plate
hour
incub
cell
process
intracellular
rna
well
extract
rneasi
kit
qiagen
level
hcv
rna
determin
revers
transcriptaser
time
pcr
assay
use
onestep
rtpcr
master
mix
reagent
appli
biosystem
foster
citi
ca
abi
prism
sequenc
detect
system
appli
biosystem
cytotox
effect
measur
ribosom
rna
control
reagent
appli
biosystem
indic
cell
number
amount
hcv
rna
ribosom
rna
use
deriv
applic
ec
valu
concentr
would
inhibit
replicon
replic
cell
stabli
replic
robustli
hbv
treat
dmso
tenofovir
alv
concentr
effect
hbv
replic
monitor
treat
cell
test
articl
relev
concentr
day
remov
supernat
retreat
analyz
addit
hour
hbsag
elisa
hbeag
elisa
hbv
dna
triplic
cell
extract
data
use
gener
testcontrol
valu
plot
test
articl
concentr
use
calcul
ic
valu
cell
transfect
hbv
dna
presenc
dmso
tenofovir
alv
alisporivir
day
amount
de
novo
hbsag
protein
present
cell
extract
supernat
quantifi
elisa
triplic
use
calcul
testcontrol
valu
antivir
efficaci
hiv
may
test
follow
blood
deriv
tlymphocyt
macrophag
isol
describ
previous
briefli
human
pbmc
purifi
fresh
blood
band
ficollhypaqu
minut
g
primari
human
cell
purifi
pbmc
posit
select
dynabead
subsequ
releas
use
detachabead
cell
cultur
rpmi
medium
invitrogen
supplement
fc
mem
amino
acid
lglutamin
mem
vitamin
sodium
pyruv
penicillin
plu
streptomycin
subsequ
activ
bacteri
superantigen
staphylococc
enterotoxin
b
seb
ngml
mitomycin
ckill
pbmc
anoth
donor
pbmc
cell
ratio
three
day
stimul
cell
split
medium
contain
unitsml
final
concentr
cultur
split
everi
day
medium
infect
hiv
day
stimul
gener
primari
human
macrophag
monocyt
purifi
human
pbmc
neg
select
activ
cultur
cell
concentr
ml
dmem
supplement
fc
mem
amino
acid
lglutamin
mem
vitamin
sodium
pyruv
penicillin
unitsml
streptomycin
mgml
ngml
recombin
human
granulocytemacrophag
colonystimul
factor
gmcsf
maintain
humidifi
atmospher
supplement
co
obtain
monocytederiv
macrophag
cell
allow
adher
plastic
cultur
day
allow
differenti
stock
viru
prepar
transfect
cell
collect
supernat
day
supernat
filter
aliquot
frozen
use
amount
viru
quantifi
elisa
infect
viral
stock
verifi
use
helabetagalactosidas
report
cell
human
fetal
thymu
liver
obtain
advanc
bioscienc
resourc
accord
feder
state
local
regul
coimplant
thymu
liver
fragment
kidney
capsul
creat
scidhu
thyliv
mice
inocul
thyliv
implant
per
thyliv
implant
direct
inject
carri
describ
male
scid
model
homozyg
mice
obtain
week
age
tacon
cohort
scidhu
thyliv
mice
implant
tissu
singl
donor
implant
inocul
week
implant
stock
viru
complet
dmem
control
infect
direct
inject
anim
protocol
approv
tsri
institut
anim
care
use
committe
group
mice
treat
alisporivir
alv
mgkgday
twicedaili
oral
gavag
implant
collect
week
inocul
implant
dispers
nylon
mesh
singlecel
suspens
assess
elisa
elisa
intracellular
gag
cell
viral
rna
bdna
assay
cell
deplet
thymocyt
subset
flow
cytometri
describ
previous
specif
implant
cell
stain
phycoerythrin
cyanin
dye
bd
bioscienc
phycoerythrin
cyanin
caltag
allophycocyanin
cyanin
ebiosci
phycoerythrinconjug
dakocytom
cell
fix
permeabil
paraformaldehyd
tween
stain
fluorescein
isothiocyanateconjug
beckman
coulter
analyz
lsr
ii
bd
bioscienc
collect
total
cell
event
percentag
markerposit
thymocyt
implant
sampl
determin
first
gate
live
lymphoid
cell
popul
identifi
forwardand
sidescatt
characterist
express
total
rna
extract
frozen
thymocyt
pellet
use
trizol
ls
invitrogen
resuspend
nucleasefre
water
capsid
region
gag
amplifi
rtpcr
use
purifi
rna
amplitaq
gold
appli
biosystem
accord
manufactur
instruct
refer
web
version
pubm
central
supplementari
materi
moss
et
al
describ
gener
preclin
analysi
bacteri
natur
product
activ
host
target
antivir
drug
gener
combin
biosynthet
engin
semisynthet
chemistri
bring
togeth
advantag
method
effici
optimis
bacteri
produc
genet
encod
natur
product
preclin
analysi
reveal
potent
activ
hcv
hiv
hbv
significantli
improv
profil
compar
parent
natur
product
cyclosporin
csa
class
cyclophilin
inhibitor
alisporivir
phase
iii
treatment
chronic
hcv
infect
optim
preclin
analysi
bacteri
natur
product
combin
bioengin
semisynthet
chemistri
preclin
analysi
reveal
potent
antivir
activ
overview
bio
synthet
medicin
chemistri
rout
gener
mean
blood
concentrationtim
profil
follow
singl
po
dose
mgkg
mice
sd
rat
beagl
dog
comparison
implant
level
tlymphocyt
rna
scidhu
thyliv
mous
model
follow
bidaili
dose
either
mgkg
alisporivir
alv
two
week
compar
untreat
mice
